Interview: Arvelle Aims To Be Major Player In CNS
Epilepsy Drug Cenobamate Filed in Europe
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
